Key statistics
On Monday, Athira Pharma Inc (ATHA:NSQ) closed at 0.6275, 52.49% above the 52 week low of 0.4115 set on Sep 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.63 |
---|---|
High | 0.65 |
Low | 0.6156 |
Bid | 0.615 |
Offer | 0.65 |
Previous close | 0.642 |
Average volume | 784.28k |
---|---|
Shares outstanding | 38.44m |
Free float | 31.66m |
P/E (TTM) | -- |
Market cap | 24.68m USD |
EPS (TTM) | -2.85 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
- Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
- Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
- Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
- Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
- Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
- Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
- Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
- Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
- Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
- Athira Pharma to Participate in Upcoming June Conferences
More ▼